search
Back to results

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Ipragliflozin
Sitagliptin
Sponsored by
Seoul National University Bundang Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Ipragliflozin, Sitagliptin

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes with HbA1c 7.5% - 9.0% at screening visit
  • Male or female between 20 and 75 years of age
  • Patients taking sulfonylurea (glimepiride 1~8mg or gliclazide 30~120 mg or equivalent dose) and metformin (≥ 1000 mg or maximum tolerated dose) for more than 3 months
  • BMI ≥23 kg/m²
  • Estimated GFR ≥ 60 ml/min/1.73m²
  • Women of child bearing potential must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose and must have a negative urinary pregnancy test.

Exclusion Criteria:

  • Type 1 diabetes, gestational diabetes, or diabetes with secondary cause
  • Patients with acute coronary syndrome within 3 months prior to screening visit
  • Patients with acute coronary syndrome within 3 months prior to screening visit
  • Pregnant or breastfeeding women or reproductive-age women who refuse contraception
  • Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT > 3-fold the upper limit of normal)
  • Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment) except thyroid cancer or carcinoma in situ
  • Other clinical trials within 30 days
  • Alcohol abuse
  • Contraindication to SGLT2 inhibitors or Dipeptidyl-peptidase 4 inhibitors
  • Taking insulin, oral hypoglycemic agents other than metformin, sulfonylurea, and the study drugs.

Sites / Locations

  • Seoul National University Bundang Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Ipragliflozin

Sitagliptin

Arm Description

Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin ** Metformin and sulfonylurea's dosages Metformin 500 mg - 2550 mg Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg

Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin ** Metformin and sulfonylurea's dosages Metformin 500 mg - 2550 mg Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg

Outcomes

Primary Outcome Measures

Glycated hemoglobin
Change of HbA1c after 24 weeks' treatment

Secondary Outcome Measures

Glycemic target goal achievement
Glycemic target goal achievement (HbA1c < 7%) at week 24
Body weight
Change of body weight at week 24
Body fat mass
Change of body fat mass at week 24
Fasting plasma glucose level
Change of fasting plasma glucose level at week 24
Postprandial 2hr glucose level
Changes of postprandial 2hr glucose level at week 24
Blood Pressure
Change of systolic/diastolic blood pressure at week 24
Triglyceride/HDL-cholesterol ratio
Changes of triglyceride/HDL-cholesterol ratio at week 24
Uric acid
Changes of uric acid at week 24
Parathyroid hormone
Changes of parathyroid hormone at week 24
25-hydroxyvitamin D
Changes of 25-hydroxyvitamin D at week 24

Full Information

First Posted
March 6, 2017
Last Updated
October 1, 2022
Sponsor
Seoul National University Bundang Hospital
Collaborators
Astellas Pharma Korea, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03076112
Brief Title
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Official Title
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
April 25, 2017 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
August 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Bundang Hospital
Collaborators
Astellas Pharma Korea, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objectives of this study are 1) to compare the effect of ipragliflozin 50 mg on glucose-lowering effect with sitagliptin 100 mg in patients with type 2 diabetes mellitus, whose HbA1c level is ≥ 7.5% with sulfonylurea and metformin, 2) to investigate changes of other metabolic and cardiovascular risk factors such as triglyceride, HDL-cholesterol, uric acid, blood pressure, and inflammatory markers, 3) to examine changes of body composition including fat and muscle mass with volume status.
Detailed Description
The objectives of this study are to compare the effect of 50mg of ipragliflozin, a SGLT2 inhibitor, on glucose-lowering effect with 100mg of sitagliptin, a DPP4 inhibitor in patients with type 2 diabetes mellitus, whose HbA1c level is ≥ 7.5% with sulfonylurea and metformin. We are also going to investigate changes of other metabolic and cardiovascular risk factors such as triglyceride, HDL-cholesterol, uric acid, blood pressure, and inflammatory markers. Changes of body composition including fat and muscle mass with volume status will be also examined.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Ipragliflozin, Sitagliptin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ipragliflozin
Arm Type
Experimental
Arm Description
Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin ** Metformin and sulfonylurea's dosages Metformin 500 mg - 2550 mg Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg
Arm Title
Sitagliptin
Arm Type
Active Comparator
Arm Description
Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin ** Metformin and sulfonylurea's dosages Metformin 500 mg - 2550 mg Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg
Intervention Type
Drug
Intervention Name(s)
Ipragliflozin
Other Intervention Name(s)
Suglat
Intervention Description
Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
Primary Outcome Measure Information:
Title
Glycated hemoglobin
Description
Change of HbA1c after 24 weeks' treatment
Time Frame
Baseline, week 12, week 24
Secondary Outcome Measure Information:
Title
Glycemic target goal achievement
Description
Glycemic target goal achievement (HbA1c < 7%) at week 24
Time Frame
Baseline, week 12, week 24
Title
Body weight
Description
Change of body weight at week 24
Time Frame
Baseline, week 12, week 24
Title
Body fat mass
Description
Change of body fat mass at week 24
Time Frame
Baseline, week 24
Title
Fasting plasma glucose level
Description
Change of fasting plasma glucose level at week 24
Time Frame
Baseline, week 12, week 24
Title
Postprandial 2hr glucose level
Description
Changes of postprandial 2hr glucose level at week 24
Time Frame
Baseline, week 12, week 24
Title
Blood Pressure
Description
Change of systolic/diastolic blood pressure at week 24
Time Frame
Baseline, week 12, week 24
Title
Triglyceride/HDL-cholesterol ratio
Description
Changes of triglyceride/HDL-cholesterol ratio at week 24
Time Frame
Baseline, week 12, week 24
Title
Uric acid
Description
Changes of uric acid at week 24
Time Frame
Baseline, week 12, week 24
Title
Parathyroid hormone
Description
Changes of parathyroid hormone at week 24
Time Frame
Baseline, week 12, week 24
Title
25-hydroxyvitamin D
Description
Changes of 25-hydroxyvitamin D at week 24
Time Frame
Baseline, week 12, week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes with HbA1c 7.5% - 9.0% at screening visit Male or female between 20 and 75 years of age Patients taking sulfonylurea (glimepiride 1~8mg or gliclazide 30~120 mg or equivalent dose) and metformin (≥ 1000 mg or maximum tolerated dose) for more than 3 months BMI ≥23 kg/m² Estimated GFR ≥ 60 ml/min/1.73m² Women of child bearing potential must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose and must have a negative urinary pregnancy test. Exclusion Criteria: Type 1 diabetes, gestational diabetes, or diabetes with secondary cause Patients with acute coronary syndrome within 3 months prior to screening visit Patients with acute coronary syndrome within 3 months prior to screening visit Pregnant or breastfeeding women or reproductive-age women who refuse contraception Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT > 3-fold the upper limit of normal) Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment) except thyroid cancer or carcinoma in situ Other clinical trials within 30 days Alcohol abuse Contraindication to SGLT2 inhibitors or Dipeptidyl-peptidase 4 inhibitors Taking insulin, oral hypoglycemic agents other than metformin, sulfonylurea, and the study drugs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Soo Lim
Organizational Affiliation
Seoul National University Bundang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
State/Province
Gyeonggi
ZIP/Postal Code
463-707
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Yes
Citations:
PubMed Identifier
25643044
Citation
Hedrington MS, Davis SN. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):613-23. doi: 10.1517/17425255.2015.1009893. Epub 2015 Feb 2.
Results Reference
background
PubMed Identifier
25316572
Citation
Kadokura T, Zhang W, Krauwinkel W, Leeflang S, Keirns J, Taniuchi Y, Nakajo I, Smulders R. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clin Pharmacokinet. 2014 Nov;53(11):975-88. doi: 10.1007/s40262-014-0180-z.
Results Reference
background
PubMed Identifier
22795925
Citation
Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther. 2012 Aug;34(8):1761-71. doi: 10.1016/j.clinthera.2012.06.027. Epub 2012 Jul 15.
Results Reference
background
PubMed Identifier
25311502
Citation
Takasu T, Hayashizaki Y, Tahara A, Kurosaki E, Takakura S. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. Clin Exp Pharmacol Physiol. 2015 Jan;42(1):87-93. doi: 10.1111/1440-1681.12317.
Results Reference
background
PubMed Identifier
22587345
Citation
Smulders RA, Zhang W, Veltkamp SA, van Dijk J, Krauwinkel WJ, Keirns J, Kadokura T. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012 Oct;14(10):937-43. doi: 10.1111/j.1463-1326.2012.01624.x. Epub 2012 Jun 7.
Results Reference
background
PubMed Identifier
20880347
Citation
Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, Poucher SM. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12. doi: 10.1111/j.1463-1326.2010.01291.x.
Results Reference
background
PubMed Identifier
23906445
Citation
Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 Feb;16(2):159-69. doi: 10.1111/dom.12189. Epub 2013 Aug 29.
Results Reference
background
PubMed Identifier
25592197
Citation
Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S; Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015 Mar;38(3):365-72. doi: 10.2337/dc14-0666. Epub 2015 Jan 15.
Results Reference
background
PubMed Identifier
17593236
Citation
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007 Sep;9(5):733-45. doi: 10.1111/j.1463-1326.2007.00744.x. Epub 2007 Jun 26.
Results Reference
background

Learn more about this trial

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

We'll reach out to this number within 24 hrs